This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gold, B. Articles by Offit, K. Search for Related Content PubMed PubMed Citation Articles by Gold, B. Articles by Offit, K.

Estrogen Receptor Genotypes and Haplotypes Associated with Breast Cancer Risk

¹ Human Genetics Section, Laboratory of Genomic Diversity, National Cancer Institute at Frederick, Frederick, Maryland; ² Celera Diagnostics or Celera, Inc, Rockville, Maryland or Alameda, California; ³ SAIC-Frederick, Inc, Frederick, Maryland; ⁴ Memorial Sloan-Kettering Cancer Center, New York, New York; ⁵ Applied Biosystems, Rockville, Maryland; ⁶ Department of Mathematics, Massachusetts Institute of Technology, Cambridge, Massachusetts; and ⁷ Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee

Nearly one in eight US women will develop breast cancer in their lifetime. Most breast cancer is not associated with a hereditary syndrome, occurs in postmenopausal women, and is estrogen and progesterone receptor-positive. Estrogen exposure is an epidemiologic risk factor for breast cancer and estrogen is a potent mammary mitogen. We studied single nucleotide polymorphisms (SNPs) in estrogen receptors in 615 healthy subjects and 1011 individuals with histologically confirmed breast cancer, all from New York City. We analyzed 13 SNPs in the progesterone receptor gene (PGR), 17 SNPs in estrogen receptor 1 gene (ESR1), and 8 SNPs in the estrogen receptor 2 gene (ESR2). We observed three common haplotypes in ESR1 that were associated with a decreased risk for breast cancer [odds ratio (OR), O.4; 95% confidence interval (CI), 0.2–0.8; P < 0.01]. Another haplotype was associated with an increased risk of breast cancer (OR, 2.1; 95% CI, 1.2–3.8; P < 0.05). A unique risk haplotype was present in 7% of older Ashkenazi Jewish study subjects (OR, 1.7; 95% CI, 1.2–2.4; P < 0.003). We narrowed the ESR1 risk haplotypes to the promoter region and first exon. We define several other haplotypes in Ashkenazi Jews in both ESR1 and ESR2 that may elevate susceptibility to breast cancer. In contrast, we found no association between any PGR variant or haplotype and breast cancer. Genetic epidemiology study replication and functional assays of the haplotypes should permit a better understanding of the role of steroid receptor genetic variants and breast cancer risk.

This article has been cited by other articles:

				H. Grans, M. Nilsson, K. Dahlman-Wright, and B. Evengard Reduced levels of oestrogen receptor {beta} mRNA in Swedish patients with chronic fatigue syndrome J. Clin. Pathol., February 1, 2007; 60(2): 195 - 198. [Abstract] [Full Text] [PDF]

				The Breast Cancer Association Consortium Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst, October 4, 2006; 98(19): 1382 - 1396. [Abstract] [Full Text] [PDF]

				L. Dossus, F. Canzian, R. Kaaks, A. Boumertit, and E. Weiderpass No Association between Progesterone Receptor Gene +331G/A Polymorphism and Endometrial Cancer. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1415 - 1416. [Full Text] [PDF]

				K. A. Pooley, C. S. Healey, P. L. Smith, P. D.P. Pharoah, D. Thompson, L. Tee, J. West, C. Jordan, D. F. Easton, B. A.J. Ponder, et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 675 - 682. [Abstract] [Full Text] [PDF]

				G. S. Huggins, J. Y.Y. Wong, S. E. Hankinson, and I. De Vivo GATA5 Activation of the Progesterone Receptor Gene Promoter in Breast Cancer Cells Is Influenced by the +331G/A Polymorphism Cancer Res., February 1, 2006; 66(3): 1384 - 1390. [Abstract] [Full Text] [PDF]

				M. T. Landi, P. A. Kanetsky, S. Tsang, B. Gold, D. Munroe, T. Rebbeck, J. Swoyer, M. Ter-Minassian, M. Hedayati, L. Grossman, et al. MC1R, ASIP, and DNA Repair in Sporadic and Familial Melanoma in a Mediterranean Population J Natl Cancer Inst, July 6, 2005; 97(13): 998 - 1007. [Abstract] [Full Text] [PDF]

				G. S. Hageman, D. H. Anderson, L. V. Johnson, L. S. Hancox, A. J. Taiber, L. I. Hardisty, J. L. Hageman, H. A. Stockman, J. D. Borchardt, K. M. Gehrs, et al. From The Cover: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration PNAS, May 17, 2005; 102(20): 7227 - 7232. [Abstract] [Full Text] [PDF]